[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"brain-infarction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:brain-infarction":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,80,105,147],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100631197","phase-3-normal-saline-infusion-after-intravenous-thrombolysis-in-stroke-100631197",false,"NCT07497542","Normal Saline Infusion After Intravenous Thrombolysis in Stroke","Safety and Efficacy of Immediate Abundant Intravenous Normal Saline Infusion for Stroke After Intravenous Thrombolysis: a Multi-centre Randomized Controlled Phase III Trial","Inclusion Criteria:\n\n1. Age 18 to 80 years.\n2. Acute ischemic stroke treated with intravenous thrombolysis.\n3. Prestroke mordified Rankin Scale score ≤1;\n4. Admission NIHSS score 4-25, with NIHSS 4-5 requiring the presence of a disabling deficit as defined in the 2026 AHA\u002FASA Guideline for the Early Management of Patients With Acute Ischemic Stroke.\n5. Onset-to-needle time≤4.5 hours or DWI-FLAIR mismatch (guided by MRI evaluation) for patients with uncertain stroke onset time according to the inclusion criteria of the WAKE-UP study.\n6. Signed informed consent.\n\nExclusion Criteria:\n\n1. Contraindications to intravenous thrombolysis.\n2. Planned endovascular treatment prior to enrollment.\n3. History of heart failure, or pre-enrollment brain natriuretic peptide (BNP) ≥100 pg\u002FmL, or clinical presentations or signs suggestive of heart failure.\n4. History of atrial fibrillation, or pre-enrollment electrocardiogram indicating atrial fibrillation.\n5. History of valvular heart disease or valve replacement surgery, suggesting cardioembolic stroke.\n6. History of renal dysfunction, or pre-enrollment serum creatinine \\>133 μmol\u002FL, or estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin\u002F1.73 m².\n7. Severe hemorrhage prior to enrollment, including symptomatic intracranial hemorrhage, gastrointestinal bleeding, respiratory tract bleeding, or massive skin and mucous membrane bleeding.\n8. Premature termination of intravenous thrombolysis due to any reason, such as hemorrhage, allergic reaction, or seizure.\n9. Participation in another clinical trial within the previous 3 months.\n10. Poor compliance, or inability to adhere to the trial protocol or complete follow-up.","ALL","18 Years","80 Years",{"count":20,"type":21},752,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The intravenous administration of abundant normal saline is an easy-to-use strategy commonly employed to expand the blood volume. This study aimed to evaluate the efficacy and safety of the early administration of an abundant normal saline infusion after intravenous thrombolysis for promoting functional independence in patients with acute ischemic stroke. This multicenter, randomized, phase III clinical trial intends to enroll stroke participants who have undergone intravenous thrombolysis. Eligible patients are randomized to receive either abundant intravenous normal saline infusion (2,000-2,500 mL; normal saline group) or a small volume of intravenous normal saline infusion (≤600 mL; control group) immediately after thrombolysis. The primary outcome is the comparison of the ordinal modified Rankin Scale score at 90 days (±3) after randomization between the treatment groups.",[27],"Brain Infarction",[29,30,31,32],"brain infarction","thrombolysis","haemodilution","normal saline","NOT_YET_RECRUITING","2026-04-19",{"date":36,"type":37},"2026-04-23","ACTUAL",{"date":39,"type":21},"2026-04",{"date":41,"type":21},"2029-09",{"name":43,"class":44},"Tianjin Medical University General Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":45},"100576378","stroke-cerebral-reorganization-pathways-spectre-100576378","NCT06784518","Stroke Cerebral Reorganization Pathways (SPECTRE)","Stroke Cerebral Reorganization Pathways Longitudinal Study After Stroke of the Clinical Motor Pattern and the Cerebral Reorganization According to the Different Damaged Motor Pathways (Main and Accessory) (SPECTRE)","SPECTRE","Inclusion Criteria:\n\n* Adult (age greater than or equal to 18 years) less than 75 years of age, both sexes;\n* single supratentorial ischemic stroke confirmed by brain imaging\n* Upper limb deficit defined by a SAFE score \\\u003C5 (SAFE Stinear protocol, prognosis of post-stroke upper limb recovery) on D3 of stroke. This corresponds to the sum of shoulder abduction and finger extension according to the MRC (Medical Research Council) scale for each of these movements out of 5.\n* Absence of comprehension disorders limiting participation;\n* Patient covered by french social security;\n* Free, informed and written consent signed by the patient or a member of the patient's family (in the case of a patient who is able to understand the information and give consent but has motor difficulties resulting in an invalid signature).\n\nNon-Inclusion Criteria:\n\n* Multiple ischemic strokes or history of clinically significant stroke ;\n* Posterior fossa stroke ;\n* Hemorrhagic stroke;\n* Patient who have undergone thrombolysis or mechanical thrombectomy;\n* Extensive Fazekas grade 3 vascular leukopathy;\n* Pre-existing neurodegenerative pathology;\n* Patient with severe dyspnea or swallowing disorders who cannot undergo brain MRI;\n* Adults under legal protection (safeguard of justice, curatorship, guardianship, family habilitation), persons deprived of liberty;\n* Women declaring that they are pregnant or breast-feeding;\n* Patient participating in another therapeutic or drug intervention study that may have an impact on the effect of cerebral neuroplasticity on the SPECTRE study;\n* Patients with contraindications to MRI pacemaker or implantable defibrillator, neurosurgical clips, cochlear implants, intra-orbital or encephalic metallic foreign bodies, stents placed less than 4 weeks ago and osteosynthesis devices placed less than 6 weeks ago, claustrophobia.\n\nExclusion Criteria:\n\n* If the prognostic group according to the PREP2 algorithm (good, limited and poor) has already been reached during motor evoked potential assessment the patient is excluded.\n* Recurrence of clinically significant stroke (with worsening NIHSS score \\> 4) during study.","75 Years",{"count":56,"type":21},30,[58],"NA","SPECTRE is a prospective longitudinal study in order to identify whether patients with different degrees of motor recovery are distinguished by distinct brain post-stroke plasticity patterns in the acute and sub-acute phases. This study allows close longitudinal follow-up of patients with severe clinical motor impairment using functional MRI to study cerebral neuroplasticity after ischemic stroke in the acute and sub-acute phase in patients with upper limb motor impairement, taking into account prognostic criteria used in current practice.",[61,62,63,27,64],"Brain Diseases","Ischemic Stroke","Stroke","Stroke Rehabilitation",[66,67,68,69,70],"stroke","Rehabilitation","Upper Limb","Neuroplasticity","Connectivity","2026-03-27",{"date":73,"type":37},"2026-04-02",{"date":75,"type":21},"2026-09-01",{"date":77,"type":21},"2029-03",{"name":79,"class":44},"Rennes University Hospital",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":45},"100507236","early-upper-limb-rehabilitation-with-eeg-neurofeedback-after-stroke-100507236","NCT05884762","earlY Upper Limb Rehabilitation WIth EEG-Neurofeedback After Stroke","YUWIN-Stroke","Inclusion Criteria:\n\n* Unilateral ischaemic or haemorrhagic stroke\n* Adult (18-80 years), both sexes\n* Stroke \\\u003C 3 weeks\n* Upper limb deficit defined by Shoulder Abduction Finger Extension score \\\u003C5 measured during the 7 days following stroke; i.e., patients predicted to have incomplete recovery\n* No participation-limiting comprehension problems\n* With or without homonymous lateral hemianopia; with or without visuospatial hemineglect\n* Free, informed and written consent signed by the patient or a member of the patient's family (in the case of a patient who is able to understand the information and give consent but has motor difficulties resulting in an invalid signature).\n* Affiliated to french social security\n\nExclusion Criteria:\n\n* Ischemic or hemorrhagic brain stem and\u002For cerebellum involvement\n* Multiple strokes\n* Stroke \\\u003C 1 week; in order not to be deleterious by starting active rehabilitation too early after immediate stroke\n* Aphasia with major comprehension impairment\n* Contraindication to MRI\n\n  * pacemaker or implantable defibrillator,\n  * neurosurgical clips,\n  * cochlear implants,\n  * intra-orbital or encephalic metallic foreign bodies,\n  * stents placed less than 4 weeks ago and osteosynthesis devices placed less than 6 weeks ago,\n  * claustrophobia. (Patients who have undergone thrombolysis or thrombectomy may be included in the study.)",{"count":88,"type":21},40,[58],"The aim of this study is to evaluate the effect of early rehabilitation treatment by electroencephalographic neurofeedback on upper limb motor function after stroke.\n\nResearchers will compare :\n\nInterventional group: electroencephalographic neurofeedback + traditional reference rehabilitation programme Control group: SHAM electroencephalographic neurofeedback + traditional reference rehabilitation programme",[63,92,93,64,27],"Stroke Hemorrhagic","Stroke, Ischemic",[63,67,95,68],"neurofeedback","RECRUITING","2026-02-26",{"date":99,"type":37},"2026-03-03",{"date":101,"type":37},"2024-02-20",{"date":103,"type":21},"2027-11",{"name":79,"class":44},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":115,"studyType":116,"phases":4,"briefSummary":117,"conditions":118,"keywords":129,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":45},"100589453","cardiac-assessment-for-recurrent-stroke-risk-evaluation-in-atrial-fibrillation-100589453","NCT06954610","Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation","CARE-AF: Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation","CARE-AF","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Written informed consent (by patient, next of kin or legally authorised representative)\n* Permanent, persistent, or paroxysmal AF previously known or diagnosed during the index hospitalisation\n* Acute (≤7 days), symptomatic ischemic stroke\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C1 year according to the opinion of the investigator\n* Patient is unlikely to attend follow-up visits",{"count":114,"type":21},500,"12 Months","OBSERVATIONAL","Background\n\nAtrial fibrillation (AF) is the most common cardiac arrhythmia, affecting up to 10% of the elderly. Ischemic stroke is the main complication of AF and cardioembolism is one of the leading causes of ischemic stroke, accounting for approximately one third of cases. Oral anticoagulant therapy (OAC) is a cornerstone in stroke prevention in patients with AF. According to randomized controlled trials of direct oral anticoagulants, a residual risk of ischemic stroke of 1-2% per year for so-called \"breakthrough stroke\" remains, despite adequate intake of OAC. The majority (\\>70%) of these breakthrough strokes are cardioembolic in nature and only a minority are related to medication issues (e.g. non-compliance) or other, non-AF related etiologies. Stroke recurrence risk after such a breakthrough stroke markedly increases to 8-9% per year indicating a particularly high-risk situation. Why OAC fails in certain patients, but not in others remains as poorly understood, as does the reason why the subsequent risk of stroke is so high.\n\nCurrent risk stratification tools, such as the widely used CHA2DS2-VA(Sc)-score, fail to predict stroke risk in such a high-risk cohort, as they were intended to guide the initiation of OAC in low to moderate risk patients. In light of new therapeutic strategies currently being investigated, such as percutaneous left atrial appendage occlusion in patients with breakthrough strokes (ELAPSE - NCT05976685) or in AF-patients deemed high-risk (LAAOS IV - NCT05963698), improved risk stratification and characterization of high-risk AF patients is highly warranted.\n\nSeveral clinical factors, such as those reflected in the CHA2DS2-VA(Sc)-score, and especially a high AF-burden are associated with increased risk of cardioembolic stroke. Several cardiac serum biomarkers are thought to be surrogates not only of cardiac function, but also of cardioembolic risk. Reflecting ventricular and atrial wall tension, myocardial injury, oxidative stress and thrombogenicity, elevated NT-proBNP, MR-proANP, high-sensitive Troponin T and D-Dimers have all been associated with cardioembolic stroke in different AF and non-AF populations. As the main location of thrombus formation, the left atrium (LA) and more specifically its appendage (LAA) are of particular interest in the pathogenesis of cardioembolism. Pronounced LA-enlargement, compared to a normal-sized LA, correlates with an increased risk of cardioembolism in AF-patients. As over 80% of thrombi form within the LAA, several LAA-characteristics, such as slower LAA-flow velocity and larger LAA-orifice area have also been demonstrated to be associated with higher stroke risk. Although there is data on each one of these factors, they have only been investigated in low to moderate risk populations, such as AF-patients without prior stroke, OAC-naïve patients, or even within the general population as a whole. Their role in high-risk AF-patients and in breakthrough stroke is unknown.\n\nHypothesis\n\nThe investigators hypothesize that specific clinical factors, serum cardiac biomarkers and markers of LA- and LAA-morphology and function are associated with breakthrough stroke \u002F OAC-failure and may improve risk stratification.\n\nMethods\n\nCARE-AF is a single-center, prospective cohort study conducted at the Stroke Center of the Inselspital, University Hospital Bern, Switzerland. Patients with an index ischemic stroke and AF (breakthrough and non-breakthrough cases) will be enrolled. The investigators will collect clinical data, serum cardiac biomarkers and echocardiographic indices of the LA and LAA. All patients will receive standardized annual follow-ups until the end of the study, defined as 12 months after the inclusion of the last participant. The primary endpoint is ischemic stroke or systemic embolism during follow-up. First, in a cross-sectional design, the study will assess the association between serum cardiac biomarkers and echocardiographic indices among patients with breakthrough vs. non-breakthrough stroke as index event, applying multivariate regression models. Second, the investigators will perform a longitudinal analysis assessing the association between the variables mentioned above and breakthrough stroke as index event with the primary endpoint, using multivariate Cox regression models. The study aims to enroll a minimum of 500 patients, which provides sufficient power to detect a clinically meaningful adjusted hazard ratio for recurrent stroke of 1.5 with 80% power at an alpha level of 5%.\n\nConclusion\n\nThe results of this project will enhance understanding of the role of specific clinical factors, cardiac serum biomarkers and echocardiographic indices in the residual risk of stroke in patients with AF on anticoagulation therapy. They may improve current risk stratification and have the potential to help guide therapeutic decisions in high-risk situations considering evolving therapeutic possibilities.",[62,119,120,61,121,122,123,124,27,125,126,63,127,128],"Atrial Fibrillation","Cerebrovascular Disorders","Central Nervous System Diseases","Vascular Diseases","Arrhythmias, Cardiac","Heart Diseases","Brain Ischemia","Infarction Cerebral","Cardioembolic Stroke","Ischemia",[130,131,132,133,134,135,136,137],"Ischemic stroke","Direct oral anticoagulation","Anticoagulation","Breakthrough stroke","Risk stratification","Atrial fibrillation","Anticoagulant therapy","Direct oral anticoagulant","2025-11-17",{"date":140,"type":37},"2025-11-20",{"date":142,"type":37},"2025-11-04",{"date":144,"type":21},"2028-06-30",{"name":146,"class":44},"Insel Gruppe AG, University Hospital Bern",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":155,"targetDuration":157,"studyType":116,"phases":4,"briefSummary":158,"conditions":159,"keywords":162,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":45},"100564794","therapy-evaluation-in-patients-with-minor-stroke-and-large-vessel-occlusion-100564794","NCT06633809","Therapy Evaluation in Patients With Minor Stroke and Large Vessel Occlusion","Therapy Evaluation in Patients With Minor Stroke and Large Vessel Occlusion: A Prospective Multicenter Registry Study","TEMPOS","Inclusion Criteria:\n\n1. Aged 18 years or older\n2. Acute ischemic stroke patients of NIHSS 0-5 with 24 hours after onset\n3. Proximal intracranial artery occlusion on NCCT\u002FCTA or MRI\u002FMRA showing occlusion of the intracranial ICA, M1, or proximal M2 vessel\n4. Baseline ASPECTS ≥6 or infarct Core Volume of \\\u003C 70 on NCCT\u002FDWI\u002FCTP\n5. Pre-mRS≤1\n\nExclusion Criteria:\n\n1. Any sign of intracranial hemorrhage on baseline CT\u002FMR;\n2. Seizures at stroke onset\n3. Baseline blood glucose of \\\u003C2.78 mmol or \\>22.20 mmol, or platelet count \\\u003C 100,000\u002FuL or serum creatinine levels \\> 3.0 mg\u002FdL\n4. Participation in any investigational study in the previous 30 days",{"count":156,"type":21},200,"90 Days","This multicenter registry study, which record the therapy strategy and follows up these acute ischemic stroke (AIS) patients with low NIHSS and large vessel occlusion (LVO), is intended to provide the important data for therapy evaluation and prognostic prediction of the LVO patients with low NIHSS.",[160,120,61,121,122,27,161],"Stroke, Acute","Nervous System Diseases",[66,163,164,165,166,167],"Mechanical thrombectomy","Proximal intracranial arterial occlusions","Large vessel occlusion","acute neurological deterioration","Outcome","2024-10-07",{"date":170,"type":37},"2024-10-09",{"date":172,"type":37},"2021-11-22",{"date":174,"type":21},"2027-03-01",{"name":176,"class":44},"Sir Run Run Shaw Hospital"]